BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB
I4V-MC-JAHX
Phase 3 small_molecule active
Quick answer
BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB for Juvenile Idiopathic Arthritis is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Juvenile Idiopathic Arthritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active